Lilly’s Alzheimer’s drug may slow patients’ decline, study shows
July 22, 2015 at 07:23 AM EDT
Eli Lilly’s Alzheimer’s treatment, solanezumab, can slow the decline of memory and function, a study shows.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.